Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship
- PMID: 34050922
- DOI: 10.1111/eci.13622
Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship
Abstract
According to the 'multiple-hit' hypothesis, several factors can act simultaneously in nonalcoholic fatty liver disease (NAFLD) progression. Increased nitro-oxidative (nitroso-oxidative) stress may be considered one of the main contributors involved in the development and risk of NAFLD progression to nonalcoholic steatohepatitis (NASH) characterized by inflammation and fibrosis. Moreover, it has been repeatedly postulated that mitochondrial abnormalities are closely related to the development and progression of liver steatosis and NAFLD pathogenesis. However, it is difficult to determine with certainty whether mitochondrial dysfunction or oxidative stress are primary events or a simple consequence of NAFLD development. On the one hand, increasing lipid accumulation in hepatocytes could cause a wide range of effects from mild to severe mitochondrial damage with a negative impact on cell fate. This can start the cascade of events, including an increase of cellular reactive nitrogen species (RNS) and reactive oxygen species (ROS) production that promotes disease progression from simple steatosis to more severe NAFLD stages. On the other hand, progressing mitochondrial bioenergetic catastrophe and oxidative stress manifestation could be considered accompanying events in the vast spectrum of abnormalities observed during the transition from NAFL to NASH and cirrhosis. This review updates our current understanding of NAFLD pathogenesis and clarifies whether mitochondrial dysfunction and ROS/RNS are culprits or bystanders of NAFLD progression.
Keywords: ROS; mitochondria; mitochondrial dysfunction; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; oxidative stress.
© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Similar articles
-
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?Int J Mol Sci. 2021 May 20;22(10):5375. doi: 10.3390/ijms22105375. Int J Mol Sci. 2021. PMID: 34065331 Free PMC article. Review.
-
Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?Liver Int. 2014 Aug;34(7):e180-90. doi: 10.1111/liv.12523. Epub 2014 Mar 28. Liver Int. 2014. PMID: 24621397 Review.
-
From Non-Alcoholic Fatty Liver to Hepatocellular Carcinoma: A Story of (Mal)Adapted Mitochondria.Biology (Basel). 2023 Apr 14;12(4):595. doi: 10.3390/biology12040595. Biology (Basel). 2023. PMID: 37106795 Free PMC article. Review.
-
Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease.World J Gastroenterol. 2014 Oct 21;20(39):14205-18. doi: 10.3748/wjg.v20.i39.14205. World J Gastroenterol. 2014. PMID: 25339807 Free PMC article. Review.
-
Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease.Biochem Pharmacol. 2019 Feb;160:34-45. doi: 10.1016/j.bcp.2018.11.020. Epub 2018 Nov 30. Biochem Pharmacol. 2019. PMID: 30508523 Review.
Cited by
-
The Effect of Adjuvant Therapy with Molecular Hydrogen on Endogenous Coenzyme Q10 Levels and Platelet Mitochondrial Bioenergetics in Patients with Non-Alcoholic Fatty Liver Disease.Int J Mol Sci. 2023 Aug 5;24(15):12477. doi: 10.3390/ijms241512477. Int J Mol Sci. 2023. PMID: 37569850 Free PMC article.
-
Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions.Front Cell Dev Biol. 2023 May 16;11:1199519. doi: 10.3389/fcell.2023.1199519. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37261074 Free PMC article. Review.
-
The Hepatoprotective Properties of Gentiopicroside, Sweroside, and Swertiamarin Against Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Biomolecules. 2025 May 16;15(5):726. doi: 10.3390/biom15050726. Biomolecules. 2025. PMID: 40427619 Free PMC article.
-
Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease.Nutrients. 2021 Nov 15;13(11):4077. doi: 10.3390/nu13114077. Nutrients. 2021. PMID: 34836332 Free PMC article. Review.
-
Metabolic Priming as a Tool in Redox and Mitochondrial Theragnostics.Antioxidants (Basel). 2023 May 10;12(5):1072. doi: 10.3390/antiox12051072. Antioxidants (Basel). 2023. PMID: 37237939 Free PMC article. Review.
References
REFERENCES
-
- Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.
-
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
-
- Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547-555.
-
- Haldar D, Kern B, Hodson J, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study. J Hepatol. 2019;71(2):313-322.
-
- Krawczyk M, Liebe R, Lammert F. Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA3 and Beyond. Gastroenterology. 2020;158(7):1865-1880.e1.
Publication types
MeSH terms
Grants and funding
- 722619/H2020 Marie Skłodowska-Curie Actions
- 734719/H2020 Marie Skłodowska-Curie Actions
- IP2015 022074/Ministerstwo Nauki i Szkolnictwa Wyższego
- ST 46/Ministerstwo Nauki i Szkolnictwa Wyższego
- POCI-01-0145-FEDER-029152/Foundation for Science and Technology (FCT)
- PTDC/ASP-HOR/29152/2017/Foundation for Science and Technology (FCT)
- UIDB/04539/2020/Foundation for Science and Technology (FCT)
- UMO-2015/17/D/NZ1/00030/Narodowe Centrum Nauki
- UMO-2018/29/B/NZ1/00589/Narodowe Centrum Nauki
- UMO-2020/36/T/NZ1/00004/Narodowe Centrum Nauki
- Operational Program Competitiveness Factors COMPETE
- European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
- European Reference Network on Hepatological Diseases (ERN RARE-LIVER)
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical